Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

17-03-2026(Tue) 16-03-2026(Mon) 13-03-2026(Fri) 12-03-2026(Thu) 11-03-2026(Wed)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
17 Apr, 2026 (Friday)

            
LUYE PHARMA(2186)
Analysis¡G
Luye Pharma is an international pharmaceutical company dedicated to the research and development, production, and sales of innovative drugs. The Group has established R&D centers in China, the United States, and Europe. It currently has over 30 domestic pipeline products under development and more than 10 pipeline products for other international markets. The Group maintains world-class standards in advanced drug delivery technologies, including microspheres, liposomes, and transdermal drug delivery systems. It has achieved multiple innovative breakthroughs in new molecular entities and antibodies, and is also actively pursuing strategic development in cutting-edge fields such as cell therapy and gene therapy. The Group is building a global supply chain, with 8 production bases established worldwide, and has implemented a Good Manufacturing Practice (GMP) quality management and control system that meets international standards. With over 30 products covering major therapeutic areas such as central nervous system (CNS), oncology, cardiovascular, and metabolic diseases ¡X among which 19 major products have established strong competitive advantages in high-incidence disease areas globally ¡X the Group¡¦s business now reaches more than 80 countries and regions. These include the world¡¦s largest pharmaceutical markets ¡X China, the United States, Europe, and Japan ¡X as well as fast-growing emerging markets.
In the Chinese market, the Group¡¦s major products hold competitive positions across its four key therapeutic areas (oncology, CNS, cardiovascular, and metabolic). Notably, its oncology, metabolic, cardiovascular, and CNS drugs rank as the 1st, 2nd, 4th, and 5th largest drug markets in China, respectively. In international markets, the Group¡¦s products are primarily positioned in the central nervous system therapeutic area. For the year ended December 31, 2025, the Group recorded revenue of RMB 6.308 billion, representing a 4.1% increase compared to 2024. Despite pricing pressure on existing products, total revenue reached a new high in nearly five years, thanks to the approval and rapid growth of new products. At the same time, net profit attributable to shareholders increased significantly from RMB 471 million in 2024 to RMB 618 million, a rise of 31.1%. This reflects a marked improvement in profitability, driven by the launch of high-margin new products and effective cost control. With rapid sales growth from newly approved products over the past three years and more new products expected to be approved and launched in the future, the Group anticipates that both revenue and profit will continue to grow steadily. As of December 31, 2025, the Group had 32 pipeline products in China at various stages of development, including 19 oncology products, 5 CNS products, and 8 other products. In addition, the Group has 15 pipeline products in various development stages in the United States, Europe, and Japan. The Group will continue to optimize its pipeline structure and increase investment in innovative molecular candidates with novel mechanisms of action.(I do not hold the above stock)
Strategy¡G
Buy-in Price: $2.90, Target Price: $3.25, Cut Loss Price: $2.75


MEIG(3268)
Analysis¡G
MEIG is a global leading provider of wireless communication modules and solutions, focusing on the R&D, production, and sales of intelligent modules (especially high-compute intelligent modules). The company pursues a dual-wheel driven strategy of "wireless communication modules + IoT solutions." On the news front, MEIG has signed an investment agreement with the Nantong Chongchuan High-tech Industrial Development Zone. The company will invest in and construct an AI R&D and advanced manufacturing industrial project within the zone, including a research center and pilot/manufacturing base for high-compute AI modules, ASIC servers, high-compute automotive SIP modules, embodied intelligence, 5G+AIoT modules, and advanced processes such as SIP packaging. The total investment in the project is RMB 300 million. According to the investment agreement, the AI R&D and advanced manufacturing project is expected to achieve the following operational targets after production: Sales target ¡V cumulative taxable sales of no less than RMB 2 billion within five years of production, including achieving taxable sales exceeding RMB 20 million by 2029, and achieving annual taxable sales of no less than RMB 1.2 billion by 2032. As a leading enterprise in the edge AI module sector, MEIG is at a historic opportunity period as AI shifts from the cloud to the terminal. With its leading technology, stable market position, and strong performance growth, the company offers solid long-term investment value.
Strategy¡G
Buy-in Price: $25.30, Target Price: $29.30, Cut Loss Price: $23.00



Geely (175.HK) - Accelerating Overseas Expansion and Premiumisation Strategy

Company Profile

Geely is one of the leading enterprises in China's self-brand passenger vehicles manufacturers. The Company's products include six major brands, Geely, Lynk & Co, Zeekr, covering the A0 to C-class passenger vehicles market.

Investment Summary

26Q1 Sales Remained Largely Flat, with Premiumisation Strategy Showing Bright Spots. In the first quarter of 2026, Geely Auto delivered a cumulative 709.4 thousand vehicles, up 0.8% yoy, setting a new record high for the same period in history and regaining the top position among domestic brands. Among them, Geely brand's China Star recorded Q1 sales of 312 thousand units, down 5.5% yoy, while Galaxy sold 239 thousand units, down 8.0% yoy.

Among the sub-brands, the premium brands delivered standout performance: LYNK&CO sold 82 thousand units, up 12.5% yoy, while Zeekr sold 77 thousand units, up 86.1% yoy. The premium SUV model Zeekr 9X achieved a smooth ramp-up, with cumulative Q1 sales exceeding 20 thousand units and March sales surpassing 10 thousand units. It is the Company's first full-size premium SUV equipped with Super Hybrid technology, and also the first to feature the SEA AI Digital Chassis and the G-Pilot H9 intelligent assisted driving system.

With an average selling price of over RMB 530 thousand, it has significantly enhanced brand strength and the profitability potential following scale-up. We believe that the launch of flagship 9-series models, such as the LYNK&CO 900, Zeekr 9X and Galaxy M9, marks the beginning of a new chapter in the Company's premiumisation strategy in the SUV segment.

Explosive Growth in Exports

In overseas markets, Geely Auto recorded cumulative exports of 203 thousand units in Q1, up 125.7% yoy, far exceeding the industry's average growth rate of 56.7%, representing explosive growth and accounting for 28.6% of total sales. In the European market, the Company has completed brand layout in five core countries¡XSpain, Germany, the Netherlands, Belgium and Luxembourg. In the Southeast Asian market, Geely Xingyuan has commenced deliveries and is gradually advancing localised production.

In Latin America and the Middle East, the LYNK&CO and Zeekr brands are accelerating market penetration. The Company has provided 2026 full-year export sales guidance of no less than 640 thousand units, with a target of 750 thousand units, equivalent to yoy growth of 52.4% to 78.6%. Export business is expected to become the most important growth driver this year.

We believe that the rapid volume expansion and high profitability of overseas markets will help offset the slowdown in domestic sales and improve profit margins.

New Energy Vehicles Account for Over Half

Geely Auto's new energy transition is entering an accelerated phase. In Q1 2026, the Company's cumulative sales of new energy vehicles reached 369.1 thousand units, up 9% yoy, with the penetration rate rising to 52%, and further increasing to 55% in March alone. From a structural perspective, plug-in hybrid models contributed more incremental growth within Geely's new energy product portfolio, up 62% yoy and currently accounting for 44%, while pure electric models declined by 13% yoy, accounting for 56%.

Recent geopolitical conflicts in the Middle East have led to volatility in oil prices, which has objectively accelerated the global adoption of electric vehicles. In the long term, this trend benefits leading automakers with advantages in products, technology, cost, and supply chains. The Company's new energy vehicle segment is expected to achieve a favourable trajectory of simultaneous volume and profit growth.

Strong Performance Last Year, Core Net Profit up 36%

According to the Company's 2025 annual report, full-year revenue reached RMB 345,232 million, up 25.1% yoy; net profit attributable to the parent company was RMB 16,852 million, up 0.2% yoy. Excluding foreign exchange gains, impairment losses, and gains from the deemed disposal of subsidiaries in 2024, core net profit attributable to the parent company amounted to RMB 14.41 billion, up 36% yoy.

The strong performance was mainly driven by robust sales growth, which led to the release of scale effects, as well as optimisation of product mix and synergies from strategic integration. In 2025, the Company recorded cumulative sales of 3,024.6 thousand units, up 39.0% yoy, of which new energy vehicle sales reached 1,687.8 thousand units, up 90.0% yoy. Gross margin in 2025 was 16.61%, up 0.1 ppts yoy; core net profit margin attributable to the parent company increased to 4.2%, up 0.5 ppts yoy.

The rising sales mix of Zeekr contributed significantly to the improvement in overall gross margin. In terms of expense ratios, the sales/administration/R&D expense ratios were 5.92%/1.88%/5.1%, respectively, representing yoy changes of -0.04/-0.39/+0.14 ppts. This was mainly due to increased investment in the R&D of new models and platforms, as well as a lower capitalisation ratio of R&D expenses.

Looking ahead, as the One Geely strategy continues to deepen, the cost reduction effect from declining expense ratios¡Xdriven by technology sharing and cost optimisation¡Xwill continue to materialise.

Investment Thesis

We revised our financial forecast and target price to HKD 26.6, equivalent to 12.5/10.8/8.4x PE ratio in 2026/2027/2028, and we give the rating of Accumulate. Closing price as at 15 April.

Geely's PE Band trend

""

Source: Wind, Company, Phillip Securities Hong Kong Research

Financial

"Financial

(Closing price as at 15 April)


Download PDF version...




Recommendation on 17-4-2026
RecommendationAccumulate
Price on Recommendation Date$ 24.040
Suggested purchase priceN/A
Target Price$ 26.600
Writer Info
Zhang Jing
(Analyst)
Tel: (+ 86 021-6351 2939)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2026 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]